Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285604187> ?p ?o ?g. }
- W4285604187 endingPage "370" @default.
- W4285604187 startingPage "362" @default.
- W4285604187 abstract "Purpose of review To summarize the development of modified T-cell therapies in sarcomas and discuss relevant published and ongoing clinical trials to date. Recent findings Numerous clinical trials are underway evaluating tumor-specific chimeric antigen receptor T cells and high affinity T-cell receptor (TCR)-transduced T cells in sarcomas. Notably, translocation-dependent synovial sarcoma and myxoid/round cell liposarcoma are the subject of several phase II trials evaluating TCRs targeting cancer testis antigens New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and melanoma antigen-A4 (MAGE A4), and response rates of up to 60% have been observed for NY-ESO-1 directed, modified T cells in synovial sarcoma. Challenges posed by modified T-cell therapy include limitations conferred by HLA-restriction, non-immunogenic tumor microenvironments (TME), aggressive lymphodepletion and immune-mediated toxicities restricting coinfusion of cytokines. Summary Cellular therapy to augment the adaptive immune response through delivery of modified T cells is an area of novel therapeutic development in sarcomas where a reliably expressed, ubiquitous target antigen can be identified. Therapeutic tools to improve the specificity, signaling, proliferation and persistence of modified TCRs and augment clinical responses through safe manipulation of the sarcoma TME will be necessary to harness the full potential of this approach." @default.
- W4285604187 created "2022-07-16" @default.
- W4285604187 creator A5003779074 @default.
- W4285604187 creator A5026451121 @default.
- W4285604187 creator A5032930336 @default.
- W4285604187 creator A5048969933 @default.
- W4285604187 creator A5076952732 @default.
- W4285604187 creator A5079945732 @default.
- W4285604187 date "2022-07-01" @default.
- W4285604187 modified "2023-09-23" @default.
- W4285604187 title "Immunotherapy of sarcomas with modified T cells" @default.
- W4285604187 cites W1541816872 @default.
- W4285604187 cites W1572718168 @default.
- W4285604187 cites W1909138317 @default.
- W4285604187 cites W1970087181 @default.
- W4285604187 cites W1985594917 @default.
- W4285604187 cites W1985981664 @default.
- W4285604187 cites W1990255585 @default.
- W4285604187 cites W2006987944 @default.
- W4285604187 cites W2008633460 @default.
- W4285604187 cites W2020312840 @default.
- W4285604187 cites W2027863358 @default.
- W4285604187 cites W2050302632 @default.
- W4285604187 cites W2070748533 @default.
- W4285604187 cites W2094652659 @default.
- W4285604187 cites W2098357256 @default.
- W4285604187 cites W2099560139 @default.
- W4285604187 cites W2100427081 @default.
- W4285604187 cites W2106511557 @default.
- W4285604187 cites W2107026736 @default.
- W4285604187 cites W2117914559 @default.
- W4285604187 cites W2121431601 @default.
- W4285604187 cites W2127734125 @default.
- W4285604187 cites W2130011407 @default.
- W4285604187 cites W2131638796 @default.
- W4285604187 cites W2132923173 @default.
- W4285604187 cites W2136344041 @default.
- W4285604187 cites W2143626441 @default.
- W4285604187 cites W2145985838 @default.
- W4285604187 cites W2148360952 @default.
- W4285604187 cites W2148523692 @default.
- W4285604187 cites W2153712501 @default.
- W4285604187 cites W2153952062 @default.
- W4285604187 cites W2163194305 @default.
- W4285604187 cites W2165119413 @default.
- W4285604187 cites W2165142928 @default.
- W4285604187 cites W2179882437 @default.
- W4285604187 cites W2342335701 @default.
- W4285604187 cites W2342423058 @default.
- W4285604187 cites W2395676613 @default.
- W4285604187 cites W2520149112 @default.
- W4285604187 cites W2527905628 @default.
- W4285604187 cites W2566818944 @default.
- W4285604187 cites W2589417329 @default.
- W4285604187 cites W2610035536 @default.
- W4285604187 cites W2610371878 @default.
- W4285604187 cites W2618374662 @default.
- W4285604187 cites W2750343713 @default.
- W4285604187 cites W2751012960 @default.
- W4285604187 cites W2762797139 @default.
- W4285604187 cites W2771691472 @default.
- W4285604187 cites W2773389902 @default.
- W4285604187 cites W2775369717 @default.
- W4285604187 cites W2783070348 @default.
- W4285604187 cites W2787301955 @default.
- W4285604187 cites W2787621143 @default.
- W4285604187 cites W2792937256 @default.
- W4285604187 cites W2799932748 @default.
- W4285604187 cites W2801309958 @default.
- W4285604187 cites W2807603420 @default.
- W4285604187 cites W2886819502 @default.
- W4285604187 cites W2888210354 @default.
- W4285604187 cites W2890921517 @default.
- W4285604187 cites W2903062212 @default.
- W4285604187 cites W2911188335 @default.
- W4285604187 cites W2942698526 @default.
- W4285604187 cites W2948835056 @default.
- W4285604187 cites W2965770429 @default.
- W4285604187 cites W2977941468 @default.
- W4285604187 cites W2981595408 @default.
- W4285604187 cites W2987025955 @default.
- W4285604187 cites W2990304685 @default.
- W4285604187 cites W2998268542 @default.
- W4285604187 cites W3001836957 @default.
- W4285604187 cites W3004461655 @default.
- W4285604187 cites W3005073090 @default.
- W4285604187 cites W3014683777 @default.
- W4285604187 cites W3015953783 @default.
- W4285604187 cites W3028523516 @default.
- W4285604187 cites W3030083314 @default.
- W4285604187 cites W3031718076 @default.
- W4285604187 cites W3043703771 @default.
- W4285604187 cites W3083776688 @default.
- W4285604187 cites W3099993684 @default.
- W4285604187 cites W3106984112 @default.
- W4285604187 cites W3107964318 @default.
- W4285604187 cites W3120422386 @default.
- W4285604187 cites W3158959815 @default.